Current stock page

Stock Analysis

Bruker Corporation (BRKR) Stock Analysis

Bruker Corporation (BRKR) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

BRKR Stock Analysis Summary

Bruker Corporation (BRKR) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 83/100. Risk is the weakest current factor at 44/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 18, 2026 · Market-close data

BRKR at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$63.26
AIQ Score64/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Buy
Market Cap$9.39B
P/E Ratio (TTM)-55.83
Forward P/E—
EPS (Q3 FY2026)-$0.81
Revenue (Q3 FY2026)$874M
Dividend Yield (TTM)0.33%
Beta1.73
Volume1.73M
52-week range$32.37-$68.98
RSI 1452.52
50-Day SMA$59.48
200-Day SMA$50.82
Analyst Price Target$71.67
Next EarningsFeb 11, 2027
As of Nov 18, 2026 · Market close

BRKRBruker Corporation

Healthcare / Medical - Devices

Low Priority

Above Peers

NeutralEdge 7/10
$63.26+$1.90 (+3.10%)

Latest quote

  • Momentum
    83
  • Value
    53
  • Quality
    60
  • Risk resilience
    44
  • Sentiment
    —
algovestiq.comScore data as of Nov 18, 2026

BRKR Stock Analysis Summary

Bruker Corporation (BRKR) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 83/100. Risk resilience is the weakest current factor at 44/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 18, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, BRKR has AIQ Score of 64/100 with Momentum base of 83/100 and fading Risk resilience at 44/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (83/100) leads while Risk resilience (44/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 3.10% stock move · BRKR classified in Medical - Devices.

Current Evidence

NeutralBRKR is in a neutral AIQ regime; Momentum is the strongest visible factor at 83/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is BRKR Bullish or Bearish Right Now?

BRKR currently has a neutral overall setup. Momentum is the strongest factor at 83/100, while Risk Resilience is weakest at 44/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Momentum is constructive at 83/100.
  • - Price is +3.54% above its 50-day SMA.
  • - Analyst target implies +13.29% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (31 vs 5).
Bear Case
  • - Risk Resilience is weak at 44/100.

Current Consensus

BRKR's Technical Analysis Consensus is currently Strong Buy, with 31 buy, 10 neutral, and 5 sell votes. BRKR's 14-day RSI is 52.52, which places the stock in a neutral momentum range. BRKR's beta is 1.73, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in BRKR?

The largest recent change in BRKR is Value moving down by 2.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+0.0
Momentum
+0.0
Quality
+1.0
Risk
+1.0

What Would Change the BRKR Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

BRKR Decision Framework

Public evidence layers, setup checks, and risk context for Bruker Corporation.

Bruker Corporation (BRKR) Stock Analysis

Bruker Corporation has an AIQ Score of 64/100 in a Neutral regime. Momentum is strongest at 83/100. Beta is 1.73, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextBRKR is in a Neutral AIQ regime with score 64/100.
Signal ConflictThe primary conflict is that momentum leads at 83/100 while risk lags at 44/100.
Factor EvidenceMomentum 83/100 · Value 53/100 · Quality 60/100 · Risk 44/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 83/100.

TimingPass

Momentum is 83/100 and RSI (14) is 52.5.

Regime fitWait

BRKR is in a Neutral regime at 64/100.

Risk controlFail

Risk factor is 44/100 with beta 1.73 and annual volatility 59.79%.

ConflictWait

Current conflict: momentum leads at 83/100 while risk lags at 44/100.

AIQ Score
64/100
Price
$63.26
Beta
1.73
RSI (14)
52.5

BRKR Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

BRKR Fundamentals

BRKR valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$874M
Net income
-$111.8M
Free cash flow
$96.7M
View full BRKR fundamental analysis

BRKR Technical Analysis

BRKR technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
52.52
Price vs SMA-50
+3.54%
View full BRKR technical analysis

BRKR Stock Catalysts

Track BRKR earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 11, 2027
Analyst target
$71.67
News items
4
View BRKR earnings and stock catalysts

BRKR Dividend Analysis

BRKR dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.32%
Annual dividend
$0.20
Payout ratio
—
View BRKR dividend history and analysis

BRKR Financial Data

BRKR revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$874M
EPS
-$0.81
Periods
8
View BRKR financials

BRKR Risk Analysis

BRKR volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.73
Risk score
44/100
1Y volatility
59.79%
View BRKR risk analysis

BRKR Stock News

BRKR stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 18, 2026
Sentiment
—
Read BRKR stock news

BRKR vs Medical - Devices Peers

Current peer cohort: BRKR · CNMD · ESTA · GKOS · HAE. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
BRKR
Current stock
64/10053/10083/10044/1000.8959.79%Current
CNMD
CONMED Corporation
71/10084/10074/10058/1000.4846.99%BRKR vs CNMD
ESTA
Establishment Labs Holdings Inc.
48/10032/10058/10047/1000.3549.89%BRKR vs ESTA
GKOS
Glaukos Corporation
65/10030/10090/10057/1001.8361.36%BRKR vs GKOS
HAE
Haemonetics Corporation
77/10060/10091/10067/1001.3541.04%BRKR vs HAE
Pairwise Compare links: CNMD · ESTA · GKOS · HAEBRKR vs CNMDBRKR vs ESTABRKR vs GKOSBRKR vs HAECompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 18, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 18, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a BRKR stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for BRKR: historical return with reinvested dividends, dollar-cost averaging (DCA) backtest and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 19, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-55.83
As of Nov 18, 2026
Revenue growth
1.57%
Gross margin
47.93%
Current debt / equity
0.75
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$874M
Quarter net income
-$111.8M
Quarter free cash flow
$96.7M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Mixed
RSI 14
52.52
MACD
0.84

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
44/100
Beta
1.73
Annual volatility
59.79%
Max drawdown
-39.85%

BRKR Stock FAQ

What is BRKR stock price today?

Bruker Corporation's current stock price is $63.26. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is BRKR bullish or bearish right now?

BRKR's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is BRKR's market cap?

BRKR's market cap is $9.39B based on the latest completed market-close snapshot from Nov 18, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is BRKR's current P/E ratio?

BRKR's current P/E ratio is -55.83 based on the latest completed market-close snapshot from Nov 18, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is BRKR's RSI?

BRKR's 14-day RSI is 52.52 based on the latest completed market-close snapshot from Nov 18, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is BRKR above its 50-day and 200-day moving averages?

BRKR is 3.54% from its 50-day SMA and 21.20% from its 200-day SMA based on the latest completed market-close snapshot from Nov 18, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is BRKR's next earnings date?

BRKR's next earnings date is currently listed as Feb 11, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does BRKR pay a dividend?

BRKR's dividend yield is 0.33% based on the latest completed market-close snapshot from Nov 18, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.